Trenton T. Ross

机构：Pfizer (United States)

发表论文 30 篇 · 总被引 1451 次 · h-index 15

代表论文

• An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) (2024 · Nature Metabolism · 被引 245)
• ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials (2021 · Nature Medicine · 被引 220)
• Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis (2023 · ˜The œLancet. Gastroenterology & hepatology · 被引 199)
• Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems (2020 · Cellular and Molecular Gastroenterology and Hepatology · 被引 93)
• Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction (2021 · Molecular Metabolism · 被引 89)
• De novo lipogenesis is essential for platelet production in humans (2020 · Nature Metabolism · 被引 49)